



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

11 September 2026
EMA/CVMP/194093/2026
Committee for Veterinary Medicinal Products

Summary of opinion¹ (initial authorisation)

AviGate S. Typhimurium

Common name: Salmonella Typhimurium vaccine (live)

On 10 September 2026, the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion², recommending the granting of a marketing authorisation for the veterinary medicinal product AviGate S. Typhimurium, lyophilisate for use in drinking water, intended for chickens (broilers, layers and future breeders). The applicant for this veterinary medicinal product is HuVepharm.

AviGate S. Typhimurium is a vaccine containing live *Salmonella enterica*, subsp. *enterica*, serovar Typhimurium, strain Nal2/Rif9/Rtt, as active substance.

The benefit of AviGate S. Typhimurium is the active immunisation of healthy chickens to reduce faecal excretion and colonisation of internal organs with *Salmonella* Typhimurium.

Onset of immunity: 2 weeks after first vaccination.

Duration of immunity:

- Broilers: 8 weeks after one vaccination.
- Layers and future breeders: 22 weeks after third vaccination and 14 weeks after fourth vaccination when administered in accordance with the recommended vaccination schedule.

AviGate S. Typhimurium is generally well tolerated at the recommended dose.

Detailed conditions for the use of this product are described in the summary of product characteristics (SPC) which will be published in the Union Product Database (UPD) and will be available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

The CVMP, on the basis of quality, safety and efficacy data submitted, considers that there is a favourable benefit-risk balance for AviGate S. Typhimurium and therefore recommends the granting of the marketing authorisation.

¹ Summaries of opinion are published without prejudice to the Commission Decision.

² Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.

